-
1
-
-
33645461582
-
Breast-conserving therapy after neoadjuvant chemotherapy: Long-term results
-
BERIWAL S, SCHWARTZ GF, KOMARNICKY L, Garcia-Young JA. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J 2006; 12: 159-164. http://dx.doi.org/10.1111/j.1075-122X.2006.00225.x
-
(2006)
Breast J
, vol.12
, pp. 159-164
-
-
Beriwal, S.1
Schwartz, G.F.2
Komarnicky, L.3
Garcia-Young, J.A.4
-
2
-
-
27944503994
-
High prognostic significance of residual disease after neoadjuvant chemotherapy: A retrospective study in 710 patients with operable breast cancer
-
ABRIAL SC, Penault-Llorca F, DELVA R, BOUGNOUX P, LEDUC B ET AL. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005; 94: 255-263. http://dx.doi.org/10.1007/s10549-005-9008-8
-
(2005)
Breast Cancer Res Treat
, vol.94
, pp. 255-263
-
-
Abrial, S.C.1
Penault-Llorca, F.2
Delva, R.3
Bougnoux, P.4
Leduc, B.5
-
3
-
-
53049100145
-
Predictive markers of response to neoadjuvant chemotherapy in breast cancer
-
TEWARI M, KRISHNAMURTHY A, SHUKLA HS. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol 2008; 17: 301-311. http://dx.doi.org/10.1016/j.suronc.2008.03.003
-
(2008)
Surg Oncol
, vol.17
, pp. 301-311
-
-
Tewari, M.1
Krishnamurthy, A.2
Shukla, H.S.3
-
4
-
-
32144435972
-
The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer
-
HIRANO A, SHIMIZU T, IMAMURA H, WATANABE O, KINOSHITA J ET AL. The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer. Anticancer Res 2006; 26: 581-584.
-
(2006)
Anticancer Res
, vol.26
, pp. 581-584
-
-
Hirano, A.1
Shimizu, T.2
Imamura, H.3
Watanabe, O.4
Kinoshita, J.5
-
5
-
-
84655176743
-
ER, PgR, HER-2, Ki-67, topoisomerase IIalpha, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer
-
LI XR, LIU M, ZHANG YJ, WANG JD, ZHENG YQ ET AL. ER, PgR, HER-2, Ki-67, topoisomerase IIalpha, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer. Med Oncol 2011; 28 Suppl 1: S48-54. http://dx.doi.org/10.1007/s12032-010-9693-y
-
(2011)
Med Oncol
, vol.28
, Issue.SUPPL. 1
-
-
Li, X.R.1
Liu, M.2
Zhang, Y.J.3
Wang, J.D.4
Zheng, Y.Q.5
-
6
-
-
77954832064
-
Effects of neoadjuvant chemotherapy of docetaxel combined with and epirubicin or pirarubicin on breast cancer: Clinical analysis of 160 cases
-
LI XR, WANG JD, ZHANG YJ, KONG QL, MA B ET AL. Effects of neoadjuvant chemotherapy of docetaxel combined with and epirubicin or pirarubicin on breast cancer: clinical analysis of 160 cases. Zhonghua Yi Xue Za Zhi 2009; 89: 87-90.
-
(2009)
Zhonghua Yi Xue Za Zhi
, vol.89
, pp. 87-90
-
-
Li, X.R.1
Wang, J.D.2
Zhang, Y.J.3
Kong, Q.L.4
Ma, B.5
-
7
-
-
84857916102
-
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in highrisk breast cancer patients
-
HERTEL PB, TU D, EJLERTSEN B, JENSEN MB, BALSLEV E ET AL. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in highrisk breast cancer patients. Breast Cancer Res Treat 2012; 132: 225-234. http://dx.doi.org/10.1007/s10549-011-1896-1
-
(2012)
Breast Cancer Res Treat
, vol.132
, pp. 225-234
-
-
Hertel, P.B.1
Tu, D.2
Ejlertsen, B.3
Jensen, M.B.4
Balslev, E.5
-
8
-
-
77949895996
-
HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients
-
EJLERTSEN B, JENSEN MB, NIELSEN KV, BALSLEV E, RASMUSSEN BB ET AL. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 2010; 28: 984-990. http://dx.doi.org/10.1200/JCO.2009.24.1166
-
(2010)
J Clin Oncol
, vol.28
, pp. 984-990
-
-
Ejlertsen, B.1
Jensen, M.B.2
Nielsen, K.V.3
Balslev, E.4
Rasmussen, B.B.5
-
9
-
-
79957820567
-
HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
-
YAO L, LIU Y, LI Z, OUYANG T, LI J ET AL. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Ann Oncol 2011; 22: 1326-1331. http://dx.doi.org/10.1093/annonc/mdq612
-
(2011)
Ann Oncol
, vol.22
, pp. 1326-1331
-
-
Yao, L.1
Liu, Y.2
Li, Z.3
Ouyang, T.4
Li, J.5
-
10
-
-
84055213629
-
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
-
JACOT W, Lopez-Crapez E, THEZENAS S, SENAL R, FINA F ET AL. Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Res 2011; 13: R133. http://dx.doi.org/10.1186/bcr3079
-
(2011)
Breast Cancer Res
, vol.13
-
-
Jacot, W.1
Lopez-Crapez, E.2
Thezenas, S.3
Senal, R.4
Fina, F.5
-
11
-
-
84862526929
-
The clonal and mutational evolution spectrum of primary triplenegative breast cancers
-
SHAH SP, ROTH A, GOYA R, OLOUMI A, HA G ET AL. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 2012; 486: 395-399260.
-
(2012)
Nature
, vol.486
, pp. 395-399260
-
-
Shah, S.P.1
Roth, A.2
Goya, R.3
Oloumi, A.4
Ha, G.5
-
12
-
-
51049118140
-
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
-
Stemke-Hale K, Gonzalez-Angulo AM, LLUCH A, NEVE RM, KUO WL ET AL. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084-6091. http://dx.doi.org/10.1158/0008-5472.CAN-07-6854
-
(2008)
Cancer Res
, vol.68
, pp. 6084-6091
-
-
Stemke-Hale, K.1
Gonzalez-Angulo, A.M.2
Lluch, A.3
Neve, R.M.4
Kuo, W.L.5
-
13
-
-
16644393213
-
The PIK3CA gene is mutated with high frequency in human breast cancers
-
BACHMAN KE, ARGANI P, SAMUELS Y, SILLIMAN N, PTAK J ET AL. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3: 772-775. http://dx.doi.org/10.4161/cbt.3.8.994
-
(2004)
Cancer Biol Ther
, vol.3
, pp. 772-775
-
-
Bachman, K.E.1
Argani, P.2
Samuels, Y.3
Silliman, N.4
Ptak, J.5
-
14
-
-
84856767715
-
PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2based subgroups
-
CIZKOVA M, SUSINI A, VACHER S, Cizeron-Clairac G, ANDRIE UC et al. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2based subgroups. Breast Cancer Research 2012; 14: R28. http://dx.doi.org/10.1186/bcr3113
-
(2012)
Breast Cancer Research
, vol.14
-
-
Cizkova, M.1
Susini, A.2
Vacher, S.3
Cizeron-Clairac, G.4
Andrieu, C.5
-
15
-
-
35148854641
-
PI3 kinase activation and response to Trastuzumab Therapy: What's neu with herceptin resistance?
-
PARK BH, DAVIDSON NE. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Cancer Cell. 2007; 12: 297-299. http://dx.doi.org/10.1016/j.ccr.2007.10.004
-
(2007)
Cancer Cell
, vol.12
, pp. 297-299
-
-
Park, B.H.1
Davidson, N.E.2
-
16
-
-
84864945212
-
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
-
JENSEN JD, KNOOP A, LAENKHOLM AV, GRAUSLUND M, JENSEN MB ET AL. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 2012; 23: 2034-2042. http://dx.doi.org/10.1093/annonc/mdr546
-
(2012)
Ann Oncol
, vol.23
, pp. 2034-2042
-
-
Jensen, J.D.1
Knoop, A.2
Laenkholm, A.V.3
Grauslund, M.4
Jensen, M.B.5
-
17
-
-
79960980007
-
Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
-
GOLDHIRSCH A, WOOD WC, COATES AS, GELBER RD, THURLIMANN B ET AL. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747. http://dx.doi.org/10.1093/annonc/mdr304
-
(2011)
Ann Oncol
, vol.22
, pp. 1736-1747
-
-
Goldhirsch, A.1
Wood, W.C.2
Coates, A.S.3
Gelber, R.D.4
Thurlimann, B.5
-
18
-
-
0017348988
-
Assessment of response to therapy in advanced breast cancer
-
HAYWARD JL, CARBONE PP, HEUSEN JC, KUMAOKA S, SEGALOFF A ET AL. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 35: 292-298. http://dx.doi.org/10.1038/bjc.1977.42
-
(1977)
Br J Cancer
, vol.35
, pp. 292-298
-
-
Hayward, J.L.1
Carbone, P.P.2
Heusen, J.C.3
Kumaoka, S.4
Segaloff, A.5
-
19
-
-
0033050164
-
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
-
KUERER HM, NEWMAN LA, SMITH TL, AMES FC, HUNT KK ET AL. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
-
(1999)
J Clin Oncol
, vol.17
, pp. 460-469
-
-
Kuerer, H.M.1
Newman, L.A.2
Smith, T.L.3
Ames, F.C.4
Hunt, K.K.5
-
20
-
-
79952085858
-
A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue
-
LI G, LUO X, HE J, ZHU Z, YU G et al. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. Clin Chem Lab Med 2011; 49: 191-195. http://dx.doi.org/10.1515/CCLM.2011.040
-
(2011)
Clin Chem Lab Med
, vol.49
, pp. 191-195
-
-
Li, G.1
Luo, X.2
He, J.3
Zhu, Z.4
Yu, G.5
-
21
-
-
33646021021
-
A multiplex branched DNA assay for parallel quantitative gene expression profiling
-
FLAGELLA M, BUI S, ZHENG Z, NGUYEN CT, ZHANG A ET AL. A multiplex branched DNA assay for parallel quantitative gene expression profiling. Anal Biochem 2006; 352: 50-60. http://dx.doi.org/10.1016/j.ab.2006.02.013
-
(2006)
Anal Biochem
, vol.352
, pp. 50-60
-
-
Flagella, M.1
Bui, S.2
Zheng, Z.3
Nguyen, C.T.4
Zhang, A.5
-
22
-
-
84860389233
-
Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: Possible implications for targeted therapy
-
TENG YH, TAN WJ, THIKE AA, CHEOK PY, TSE GM ET AL. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res 2011; 13: R35. http://dx.doi.org/10.1186/bcr2857
-
(2011)
Breast Cancer Res
, vol.13
-
-
Teng, Y.H.1
Tan, W.J.2
Thike, A.A.3
Cheok, P.Y.4
Tse, G.M.5
-
23
-
-
69349105634
-
PIK3CA mutation associates with improved outcome in breast cancer
-
KALINSKY K, JACKS LM, HEGUY A, PATIL S, DROBNJAK M ET AL. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009; 15: 5049-5059. http://dx.doi.org/10.1158/1078-0432.CCR-09-0632
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5049-5059
-
-
Kalinsky, K.1
Jacks, L.M.2
Heguy, A.3
Patil, S.4
Drobnjak, M.5
-
24
-
-
84863338519
-
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
-
JANKU F, WHELER JJ, WESTIN SN, MOULDER SL, NAING A ET AL. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777-782. http://dx.doi.org/10.1200/JCO.2011.36.1196
-
(2012)
J Clin Oncol
, vol.30
, pp. 777-782
-
-
Janku, F.1
Wheler, J.J.2
Westin, S.N.3
Moulder, S.L.4
Naing, A.5
-
25
-
-
3042622482
-
HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues
-
OWENS MA, HORTEN BC, DA SILVA MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004; 5: 63-69. http://dx.doi.org/10.3816/CBC.2004.n.011
-
(2004)
Clin Breast Cancer
, vol.5
, pp. 63-69
-
-
Owens, M.A.1
Horten, B.C.2
Da Silva, M.M.3
-
26
-
-
33947207819
-
HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally 300 advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination
-
TIEZZI DG, ANDRADE JM, Ribeiro-Silva A, ZOLA FE, MARANA HR ET AL. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally 300 advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007; 7: 36. http://dx.doi.org/10.1186/1471-2407-7-36
-
(2007)
BMC Cancer
, vol.7
, pp. 36
-
-
Tiezzi, D.G.1
Andrade, J.M.2
Ribeiro-Silva, A.3
Zola, F.E.4
Marana, H.R.5
-
27
-
-
84862303759
-
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
-
VON MINCKWITZ G, UNTCH M, BLOHMER JU, COSTA SD, EIDTMANN H ET AL. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804304. http://dx.doi.org/10.1200/JCO.2011.38.8595
-
(2012)
J Clin Oncol
, vol.30
, pp. 1796-1804304
-
-
Von Minckwitz, G.1
Untch, M.2
Blohmer, J.U.3
Costa, S.D.4
Eidtmann, H.5
-
28
-
-
84861527388
-
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
-
CURTIS C, SHAH SP, CHIN SF, TURASHVILI G, RUEDA OM ET AL. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
-
(2012)
Nature
, vol.486
, pp. 346-352
-
-
Curtis, C.1
Shah, S.P.2
Chin, S.F.3
Turashvili, G.4
Rueda, O.M.5
-
29
-
-
35948964043
-
Different prognostic roles of 308 mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas
-
BARBARESCHI M, BUTTITTA F, FELICIONI L, COTRUPI S, BARASSI F ET AL. Different prognostic roles of 308 mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007; 13: 6064-6069. http://dx.doi.org/10.1158/1078-0432.CCR-07-0266
-
(2007)
Clin Cancer Res
, vol.13
, pp. 6064-6069
-
-
Barbareschi, M.1
Buttitta, F.2
Felicioni, L.3
Cotrupi, S.4
Barassi, F.5
-
30
-
-
77951884331
-
Association Between Gain-Of-Function Mutations In Pik3ca And Resistance To Her2-Targeted Agents In Her2-Amplified Breast Cancer Cell Lines
-
KATAOKA Y, MUKOHARA T, SHIMADA H, SAIJO N, HIRAI M ET AL. Association Between Gain-Of-Function Mutations In Pik3ca And Resistance To Her2-Targeted Agents In Her2-Amplified Breast Cancer Cell Lines. Ann Oncol 2010; 21: 255-262. http://dx.doi.org/10.1093/annonc/mdp304
-
(2010)
Ann Oncol
, vol.21
, pp. 255-262
-
-
Kataoka, Y.1
Mukohara, T.2
Shimada, H.3
Saijo, N.4
Hirai, M.5
|